Articles

Company news

A jury Friday awarded $8.3 million to a former prison guard who accused Warsaw-based DePuy Orthopaedics of knowingly marketing a faulty hip implant that was later recalled, according to the Associated Press. Jurors found that the ASR XL implant was defectively designed and caused metal poisoning and other health problems suffered by Loren Kransky after he underwent surgery in 2007. The fraud and negligence suit is the first of nearly 11,000 similar cases involving an all-metal ball-and-socket hip joint that was pulled from the market two years ago to reach trial in the United States. Others like Kransky claim the implants have left them with crippling injuries or in need of other replacement surgeries. DePuy, a subsidiary of New Jersey-based Johnson & Johnson, has set aside about $1 billion to cover costs of the recall and lawsuits.

Eli Lilly and Co. has built up a stockpile of $21 billion in overseas profits as the nation’s largest drugmakers continue to use accounting mechanisms to avoid paying U.S. taxes. According to an analysis by Bloomberg News, the nation's six biggest drugmakers avoided paying $7.05 billion in U.S. taxes last year by shifting their profits overseas—nearly double the savings they achieved a decade ago. Now those legal practices are getting increased scrutiny from members of Congress. “The right kind of tax reform could do a lot to bring corporate profits back to the United States for investment and job creation,” said Charles Grassley, a U.S. senator from Iowa, in an e-mail to Bloomberg. “The current system provides an incentive for companies to keep money overseas indefinitely.” By moving patents and trademarks overseas, drugmakers can legally record sales of their products in foreign countries, avoiding any U.S. taxes until those profits are brought back into the United States. The maneuvers helped Lilly boost its earnings per share by 16 percent last year, according to Bloomberg. Other companies increased their earnings even more. Lilly declined to comment on the story.

IUPUI students can now pursue an academic minor in neuroscience, in addition to the neuroscience major that began in the fall. The School of Science at IUPUI launched its new neuroscience program to “take advantage of a booming neuroscience industry in Indiana and across the country,” according to a statement issued March 4. The school noted that the Indiana University Health hospital system recently opened a $120 million neuroscience center next to Methodist Hospital. And the IU School of Medicine is building a neuroscience research center next door to the IU Health facility. Neuroscience is one of several fast-growing segments of the life sciences industry in Indiana. A forecast by the Indiana Department of Workforce Development predicts that life scientist positions will increase by more than 22 percent in the next five years.

Read More

Company news

The Franciscan Alliance hospital system has signed a deal with Philadelphia-based health insurer Cigna Corp. to offer an accountable care plan to Cigna’s customers in the Indianapolis area. Mishawaka-based Franciscan will use the same accountable care organization it formed in 2011 to work with the federal Medicare program. That organization includes Franciscan hospitals in Carmel, Indianapolis and Mooresville, as well as 600 physicians in central Indiana. Franciscan and Cigna will rely heavily on case managers, who will help patients, especially those with chronic diseases, navigate the health system. The case managers will use Cigna data to identify patients in need of such attention and will in some cases refer patients to Cigna’s health management and wellness programs.

Warsaw-based DePuy Orthopaedics Inc. kept selling an artificial hip implant even after the doctors it paid as consultants on the product had begun abandoning it and after the product had failed an internal test, according to internal company documents disclosed in a legal case and summarized by The New York Times. DePuy, a subsidiary of New Jersey-based Johnson & Johnson, recalled the troubled hip implant, called the Articular Surface Replacement, or ASR, in 2010. The company has been the target of 10,000 lawsuits filed by patients who had to receive a second hip implant after the ASR failed. The device has been prone to shedding large amounts of metallic debris inside patients. DePuy’s own internal estimates show they expected the ASR to fail in 40 percent of patients within five years of their hip-implant surgery.

Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, is running out of cash and struggling to find new investors. The company told Greenwood officials of its financial troubles earlier this month, which prompted the Greenwood Redevelopment Commission to vote Jan. 17 to declare Elona in default on $8.4 million of economic development incentives the city gave the company in 2010. Wendy Brewer, an attorney for the Greenwood Redevelopment Commission, said one potential investor in Elona wants the company’s exposure under the incentive programs altered as a condition of investing in Elona. “We’re continuing to talk to them,” Brewer said, adding that the company’s finances dictate that a decision be made in a couple of weeks. Greenwood loaned $6.4 million to help Elona build a 50,000-square-foot, $28 million insulin-production plant in Greenwood and hire 70 workers. The city also gave Elona $1.5 million to help it win approval for its insulin from the U.S. Food and Drug Administration and $500,000 for equipment. So far, Brewer said, Elona has made no progress on its jobs commitments. Elona, founded by a former Eli Lilly and Co. scientist, has made its business doing contract drug manufacturing for other firms. But its growth plans hinged on making a generic version of insulin, something that was not allowed in the United States until the 2010 passage of the Patient Protection & Affordable Care Act. That law called for a pathway for “biosimilar” versions of biotech drugs, including insulin. As it stands now, a drug such as Lilly’s Humulin insulin faces no generic competition even though its patent expired in 2001. Nearly a year ago, the FDA issued draft guidance on “biosimilar” drugs that indicated it would require additional clinical trials of a biosimilar drug. That means a company like Elona would have to spend significant money to test its drug in patients before the FDA would declare it similar to an existing insulin. Calls to Elona founders Ron and Donna Zimmerman were not returned Tuesday morning.

WellPoint Inc. ended the year on a high note, posting fourth-quarter sales and profit that exceeded Wall Street’s expectations. The Indianapolis-based health insurer earned $464 million, or $1.51 per share, in the three months ended Dec. 31, a 38-percent leap from the same quarter a year earlier. Excluding investment gains and one-time charges, WellPoint would have earned $1.03 per share. On that basis, analysts were expecting 95 cents per share. Membership in WellPoint’s health plans shot up nearly 8 percent in the fourth quarter to more than 36 million nationwide. That represented a net gain of  more than 2.6 million customers. The increase was entirely attributable to WellPoint’s $4.9 billion acquisition of Virginia-based Amerigroup Corp., which added 2.7 million members in Medicaid plans. But the Blue Cross Blue Shield insurer on Wednesday gave analysts a conservative forecast for 2013, due in part to a daunting list of expenses it could face. WellPoint will spend roughly $300 million this year preparing for coverage expansions under the health care overhaul coverage and changes to its Medicare Advantage business. The insurer also expects to spend as much as $125 million integrating Amerigroup into its business, and it says it could take hits from flu claims, possible cuts to Medicare funding and an increase in health care use. Counting those expenses, WellPoint expects to earn at least $7.60 per share in 2013 compared to the $8.18 per share it earned last year.

St. Vincent Health will add air medical service at Rush Memorial Hospital in Rushville. The new StatFlight helicopter base, scheduled to open in late April or early May, will be St. Vincent's fourth helicopter base in Indiana. The others are located in Anderson, Danville, North Vernon and West Lafayette. St. Vincent contracts with PHI Air Medical LLC to operate its StatFlight air medical service.

The Community Health Network hospital system has created a new partnership with Indianapolis-based Lutheran Child and Family Services to provide treatment for children who have experienced trauma and are dealing with behavioral challenges. Indianapolis-based Community will help Lutheran manage the behavioral health services for children and adolescents at Lutherwood, a youth residential treatment facility, and Trinity House, a transitional group home for young men. The collaboration also will include community-based programs previously managed separately under Indianapolis-based Gallahue Community Mental Health Center and Lutheran. Lutheran will continue to offer spiritual care programs of its own for children and their families. Community serves more than 25,000 behavioral health patients each year. Its behavioral health unit employs more than 600 physicians, psychologists, advance practice nurses, psychiatric nurses, therapists, counselors, life skills specialists and care managers.

Read More

Company news

Warsaw-based Biomet Inc. has offered to buy the trauma products business of DePuy Orthopaedics Inc. for $280 million in cash. DePuy, a unit of New Jersey-based Johnson & Johnson since 1998, also is based in Warsaw. Biomet, which designs and manufactures orthopedic products for surgical and non-surgical uses, said the deal would greatly expand its sports, extremities and trauma business. DePuy makes artificial joints and other orthopedic devices. J&J is attempting to spin off DePuy’s trauma products business as it seeks to finalize its planned $21.3 billion acquisition of Swiss medical device maker Synthes Inc. The European Commission opened an expanded probe last November of J&J's bid to buy Synthes in a deal that would make J&J the leader in the $5.5 billion trauma device market. The Brussels-based regulator is expected to rule on the acquisition by April 26. Biomet’s offer to DePuy expires June 1 but could be extended under certain circumstances.

Carmel-based CNO Financial Group Inc. has agreed to pay $9.9 million to settle allegations by regulators in four states that its Bankers Life subsidiary acted as an investment adviser and broker-dealer without proper licensing. Bankers Life sells a mix of life insurance, annuities and Medicare supplement policies to middle-income earners near or in retirement. It has 1.3 million policyholders across the U.S. and 5,600 agents in 250 U.S. locations. CNO Financial will take a $10 million first-quarter charge related to the settlement, which calls for CNO to make payments to the states of Maine, New Hampshire, Vermont and Missouri and also cover "certain costs of the investigation." An audit revealed Bankers Life was operating in some states where it was not licensed by affiliating with licensed brokers and then steering customers into its annuity products, Maine's Office of Securities said in a statement to Reuters. CNO agreed to surrender the license for its broker-dealer subsidiary, BLC Financial Services Inc, to both the SEC and regulators in Illinois, where it is based. Financial advisers working for independent broker dealers will continue to sell Bankers Life products in the settlement states.

Nyhart, an actuarial and benefits consulting firm, has opened an office in St. Louis, its third expansion in 15 months. In 2011, Nyhart merged with an Atlanta public pension firm and prior to that acquired a business group in Kansas City, Mo. Nyhart has more than 1,000 clients in 48 states, managing $14 billion in pension plan assets. Heath Merlak, an actuary at Nyhart, will head up the new office.

Arizona-based Synergy HomeCare has established a new franchise in Indianapolis. Owners George and Denise Wright will provide 24-hour non-medical care to residents in Indianapolis, Carmel and Fishers. The company typically serves the elderly, those who are recovering from significant surgery and sickness, and new mothers. The new franchise has 10 caregivers but hopes to expand to 25. Synergy HomeCare now has 138 franchises in 37 states.

Read More

Company news

Forbes blogger Peter Cohan estimates that orthopedic implant companies—including Warsaw-based Zimmer Holdings Inc. and DePuy Orthopaedics Inc.—will pay out $5 billion to cover legal claims that their all-metal hip implants have failed, causing new health issues. The metal pieces of the implants allegedly generate debris as they rub against each other, and the debris is damaging tissue, causing infections and, in extreme cases, leading to crippling complications. Cohan broadcast his prediction after the New York Times published an article on the problem last week. The Times noted that private health insurers are moving in court to recover their expenses for the follow-up medical care caused by the hip implants. The federal Medicare program is expected to follow suit. Cohan estimates there will be 30,000 claims before the issue is settled. Multiply that number by likely settlement amounts—he notes it was $147,000 per patient 10 years ago in a case involving Sulzer Orthopedics—and you get pretty close to $5 billion.

A long-running dispute between two local food companies that serve nursing homes was resolved in October by Hamilton County Judge Steve Nation. Anderson-based Rubicon Foods LLC was ordered to pay $94,600 to Indianapolis-based Darlington Cookie Co. for misappropriation of trade secrets and trespassing on computers. Rubicon is also on the hook for nearly $276,000 in attorney's fees racked up by Darlington’s law firm, Indianapolis-based Bose McKinney & Evans LLP. Darlington is led by Phil Hockemeyer, and Rubicon is led by his younger brothers, Steve and Todd Hockemeyer. All three brothers worked together at Darlington before the younger two left in 2006 to form Rubicon, claiming they were forced out. But Darlington claimed successfully that Steve and Todd Hockemeyer stole trade secrets from Darlington’s computers before leaving. Both companies make food mixes that whip up into sliced bread, rice, pasta and cookies that dissolve immediately when eaten by nursing home patients. The mixes are designed to help patients who are malnourished or sometimes even die because they can’t swallow solid food properly.

St. Vincent Randolph Hospital in Winchester will join the Indiana Telehealth Network. Construction of about 25 miles of fiber-optic cabling to the hospital will begin in the coming weeks.  Construction will be completed this summer.  The project brings broadband Internet access to the 25-bed hospital, as well as establishes a connection hub for broadband connectivity for surrounding Randolph County. The Indiana Telehealth Network already includes 23 rural hospitals and five urban partner hospitals. The network is primarily funded by the Federal Communications Commission and is administered by the Indiana Rural Health Association. St. Vincent Randolph is part of the Indianapolis-based St. Vincent Health chain of hospitals.

Read More

Company news

The Warsaw-based makers of orthopedic implants could be hurt by a new plan floated by the Centers for Medicare & Medicaid Services to target "unnecessary" medical device claims, according to the trade publication MassDevice. Medicare officials will ask doctors to provide up-front justification for certain medical equipment, especially for orthopedic and cardiac devices. The program, set to launch in 11 states next month, will flip the reimbursement system from the agency's existing "pay-and-chase" method of looking for improper payments after they've already been made. It’s more bad news for orthopedics companies—including Warsaw’s Zimmer Holdings Inc., Biomet Inc. and DePuy Orthopaedics Inc. They have already been hurt by the recession and high unemployment, as jobless patients have put off elective surgeries. The companies are also bracing for a new industry tax instituted by the 2010 health care overhaul.

Batesville-based Hill-Rom Holdings Inc. has agreed to acquire Germany-based Volker Group for $85 million in cash, pending regulatory approvals. Volker makes bed frames and other furniture for long-term care and hospital facilities. The company, which sells mainly in Europe and other foreign markets, had 2010 revenue of roughly $100 million. Hill-Rom also makes hospital beds and other equipment, as well as provides information technology components to enhance the performance of its products. Hill-Rom said Volker’s business would strengthen its product offerings in Europe, and would boost its 2012 earnings by 2 cents or 3 cents per share. The transaction is expected to close within the first quarter of 2012.

Shares of Endocyte Inc. plummeted nearly 70 percent after clinical trial results announced Dec. 13 showed the company’s experimental ovarian cancer drug led to shorter overall survival times than treatment with a standard cancer drug. Some analysts called the sell-off an overreaction, but shares of the West Lafayette-based company remained depressed nearly a week after the news. Endocyte officials stressed that the study of the drug EC145 did not include enough patients to be statistically meaningful in terms of overall survival. Also, they noted that survival rates for patients taking standard therapy were several months longer than seen in any other study. Previous clinical trial results released by Endocyte have shown that EC145 significantly increases the length of progression-free survival for ovarian cancer patients who have cancers that are resistant to treatment with common platinum-based drugs. Investors, however, assumed the worst. In the Phase 2 trial results reported Dec. 13, patients taking EC145 with the cancer drug Doxil survived a median length of 14.1 months, which was longer than in any previous study of the drug. But patients taking Doxil alone experienced median survival rates of 16.9 months.

Indianapolis-based WellPoint Inc. is feuding with St. Louis-based pharmacy benefits manager Express Scripts Inc., according to the Associated Press. Express Scripts said WellPoint, the second-largest health insurer in the nation, has raised the possibility of filing a lawsuit over contract terms and Express Scripts’ performance under that contract. But Express Scripts officials also said the companies are negotiating, and they believe they can resolve the dispute. WellPoint is disputing the implementation of some terms of the contract and "certain operational matters associated with Express Scripts' performance" under those terms. The contract between the companies went into effect on Dec. 1, 2009, after WellPoint sold its pharmacy benefit management business to Express Scripts.

Read More

Ortho firms pull back on doc payments

The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.

Read More

Company news

Researchers at the Indiana University School of Medicine plan to launch a large clinical trial of an experimental two-drug combination for treating late-stage ovarian cancer. The drug combo produced a positive effect in 70 percent of patients in a Phase 2 trial and the IU researchers said they may have discovered biomarkers that could help identify women who would respond best to the therapy. The therapy combines two chemotherapy agents, decitabine with carboplatin. The IU researchers, led by Dr. Daniela Matei, are using it for women who have become resistant to carboplatin after multiple rounds of chemotherapy. IU is now seeking grant funding for a Phase 3 trial, in which the combo therapy will be compared against other approved therapies for ovarian cancer. Their research has been supported by the National Institutes of Health, National Cancer Institute, Walther Cancer Foundation in Indianapolis and the Ovarian Cancer Research Foundation.

DePuy Orthopaedics Inc. plans to spend $27 million on manufacturing and research equipment to grow its orthopedic implant operation in Warsaw, Ind. The expansion will add no jobs to DePuy’s 1,100-person work force, but the Warsaw City Council has approved a 10-year property tax abatement on the equipment. DePuy spokeswoman Jessica Masuga told The Journal Gazette of Fort Wayne that the equipment will improve efficiency. DePuy is a subsidiary of New Jersey-based Johnson & Johnson.

West Lafayette-based Endocyte Inc. raised about $66.8 million in a secondary public offering of nearly 6.7 million shares of company stock. Shares for the offering, which began in mid-July, were priced at $12.26 each. Endocyte, which also has offices in Indianapolis, said it intends to seek permission to sell its ovarian cancer drug in Europe on a limited basis. The decision to proceed came after consultation with the European Medicines Agency and written advice from the regulators, Endocyte said in April. Endocyte shares had more than doubled in price after its initial public offering in February, before sliding in the recent market-wide decline in stocks.

Rochester Medical Implants will move its 28 employees from Rochester to Noblesville. Fulton Economic Development Corp. director Terry Lee said company officials attributed the decision to an inability to recruit needed employees to Rochester and better proximity to customers in the Indianapolis area. The Rochester Sentinel reported that a company co-owner had previously discussed plans for expanding on its eight-acre site in that city. Lee said some of the company's workers plan on transferring to the new location, with the move expected to happen by October. Rochester is about 75 miles north of Noblesville.

Read More

Company news

Eli Lilly and Co. is a two-timing lout, according to a lawsuit filed Monday by Amylin Pharmaceuticals Inc., a San Diego-based company with which Lilly has developed and co-marketed Byetta, a successful diabetes drug. Amylin’s lawsuit accuses Indianapolis-based Lilly of breaking terms of their deal by forming a similar development and marketing agreement with Germany-based Boehringer Ingelheim GmbH to sell a drug that will compete with Byetta. The competing drug, called Tradjenta, was approved for sale this month by U.S. regulators. Lilly and Boehringer formed their agreement in January. Amylin said it plans to continue working with Lilly, but it wants to keep Lilly from using the same sales force to sell both Byetta and Tradjenta. Its lawsuit was filed in U.S. District Court for the Southern District of California. Lilly’s top diabetes executive, Enrique Conterno, called Amylin’s suit “without merit.”

The U.S. Food and Drug Administration requested new data or new studies from Zimmer Holdings Inc., DePuy Orthopaedics Inc., Biomet Inc. and many other makers of orthopedic implants to see if metal-on-metal hip implants raise the level of metals in patients’ blood, according to Bloomberg News. Zimmer, DePuy and Biomet are all based in Warsaw. Zimmer spokesman Garry Clark wrote in an e-mail to Bloomberg News that his company was "working to understand the scope of the agency's request."

Ball Memorial Hospital was losing $9 million a year before Indianapolis-based Indiana University Health acquired it in 2009. Two years later, Ball executives say the Muncie hospital has swung to a $6 million gain, according to The Star Press in Muncie. Ball Memorial executives say they reduced costs via an 18-month pay freeze and by taking advantage of IU Health’s greater buying power. “If Ball Memorial is paying $10 a unit but the next day I can pay $7 because of the IU Health relationship, those cost savings are significant,” Ball Memorial chief Michael Haley told the newspaper. He added that the hospital has worked to increase patient referrals by repairing strained relationships with local physicians, many of whom were referring patients to hospitals in Fort Wayne or Indianapolis.

A consumer advocacy group says Eli Lilly and Co.’s Amyvid, an experimental imaging agent to help doctors detect Alzheimer’s disease in patients’ brains, shouldn’t be approved because it could lead to false diagnoses of the disease, according to Bloomberg News. Public Citizen, based in Washington, D.C., voiced its concerns in a letter in the Journal of the American Medical Association, criticizing a 35-person study of Amyvid published in January. Amyvid, which Lilly acquired last year in a $300 million purchase of Avid Radiopharmaceuticals Inc., was recommended in March by a U.S. Food and Drug Administration advisory panel—if Lilly developed a training program to help doctors interpret brain scans in which the agent lights up clusters of amyloid plaques, the telltale sign of Alzheimer’s. Currently, such plaques can only be observed in autopsies of deceased Alzheimer’s patients. But Public Citizen wants Amyvid tested by more doctors in more patients, because it says results so far have been unreliable. Lilly officials called the group’s claims “inaccurate.”

Read More

People

Warsaw-based Symmetry Medical Inc. named Thomas J. Sullivan president and CEO beginning Jan. 17. He replaces Brian S. Moore, who has been CEO since 2003. Moore will remain with the orthopedic supply company through June 2012 as head of business development and as a member of the board of directors. Sullivan was previously president of the supply-chain and business-process division of New Jersey-based Johnson & Johnson Health Care Systems Inc. From 2005 to 2007, Sullivan served as president of Warsaw-based DePuy Orthopaedics Inc., a unit of Johnson & Johnson. Sullivan holds an MBA degree from the Wharton School at the University of Pennsylvania.

Westfield-based consulting firm maxIT Healthcare named Mike Sweeney its president, reporting to CEO Parker Hinshaw. The 600-person firm, which advises health care clients, also promoted Reese Gomez to be executive vice president of solution management.

The Rehabilitation Hospital of Indiana named Dr. Lisa A. Lombard its new medical director. Lombard comes to the Indianapolis rehab hospital from California, where she was the chief of traumatic brain injury rehabilitation at Santa Clara Medical Center.  She also held a similar role at the University of Pittsburgh Medical Center. The Rehabilitation Hospital of Indiana is a joint venture of Clarian Health and St. Vincent Health, two Indianapolis-based hospital systems.

Read More